Post by PharmaDots

🚀 Exciting Developments in Antibody Drug Conjugates (ADCs) and Next Generation Conjugates! 🔬 🔔 Follow our page for interesting ADC updates!   🌟 Explore the latest edition of ADC Digest for this week of June 2026, featuring groundbreaking advancements in the field of Antibody Drug Conjugates.   💊 Zai Lab’s Zocilurtatug pelitecan receives EMA Orphan Drug Designation for pulmonary Neuroendocrine carcinoma   💊 FDA accepts sBLA for Genentech’s Lunsumio and Polivy combination in relapsed/refractory Large B-cell lymphoma   💊 Oncopeptides submits EMA application for Pepaxti label expansion to third-line treatment   💊 Henlius’ HLX43 in combination with Serplulimab phase 2 NSCLC trial approved in Australia   💊 Akeso’s HER3 ADC AK138D1 in combination with Ivonescimab phase 1/2 Breast cancer trial enrolls first patient   💊 Lonza grants Antharis exclusive license to develop dual-payload ADCs for GI cancers Link: https://lnkd.in/gga9vUs5 #ADC #MedicalInnovations #Innovation #ADCnews #CIScientists #Antibodydrugconjugate #cancer #competitiveintelligence